Home | Site Map | Add to Favorites Link | Send page to a Friend | Contact us | |
About Us | Products | Research and Development | Publications and Press | Clinical Trials | Latest News | Contact us |
|
10/12/2008
P-MAPA IMMUNOMODULATOR
Product Monograph
* Orange text links below, are provided to downloadable documents and detailed descriptions of available experimental data.
* * ( Content under construction)
General properties of P-MAPA
Mechanism of Action of P-MAPA
• Proposed mechanism of therapeutic action of P-MAPA
Preliminar Immunomodulating Activities
• Lymphoproliferative Effect of P-MAPA on Splenic Cells * *
• Plaques Forming in Splenic Cells Induced by P-MAPA * *
• P-MAPA effect on human toll-like receptors * *
• P-MAPA effect in dendritic cells development and maturation * *
Use of P-Mapa in Disease States
Animal Models of Infection -Intracelullar pathogens
Bacteria, protozoan and virus
• Phleboviruses -Punta toro virus
• Parvovirus and Canine distemper virus
Animal Models of cancer
• Antitumoral Effect of P-MAPA on urinary bladder cancer
• Antitumoral Effect of P-MAPA on Lewis lung carcinoma (3LL)
• Antitumoral Effect of P-MAPA on Renal carcinoma (RENCA)
• Antitumoral Effect of P-MAPA on Mammary Carcinoma and Plasmacitoma
• Antitumoral Effect of P-MAPA on Walker 256 Tumor
• Antitumoral Effect of P-MAPA on Prostate Cancer
• Antitumoral Effect of P-MAPA on Pancreatic Cancer
• Antitumoral effect of P-MAPA on Ovarian Carcinoma
•Antitumoral Effect of P-MAPA Against Lymphosarcoma-180 Solid Tumor * *
•Antitumoral Effect of P-MAPA on Ehrlich Solid Carcinoma * *
• Restoration of cell immunocompetence -natural killer cell activity, lymphocyte proliferation and cytokine profile in tumour bearing-mice * *
• Animal models of Cancer -Conclusion * *
Toxicity and Safety
Toxicity in vitro and animals
Toxicity in vitro
• Preliminar Toxicity in mitochondria - Cytotoxicity -V 79 cell line
Toxicity in Animals
Toxicity in mice
• Oral Acute Toxicity in Mice (single dose)
Toxicity in Rats
• 12 Week Multiple Dose Toxicity in Rats
• Reproduction and post-natal toxicity in rats
Toxicity in mice - Teratogenicity in mice
• Effect of P-MAPA on Intra-ocular Graft Tooth Germ Development
• Effect of P-MAPA on Tooth Germ and Palate Development
Toxicity in Monkeys
• 4 Week Multiple Dose Toxicity in primates
Pharmacokinetics
• Plasma levels of P-MAPA at diferent doses in rats
• Pharmacocinetic parameters of P-MAPA and target organs for Mg2+ ions
Preclinical conclusions
•Animal models * *
Safety in Humans
Clinical Trials
• Clinical Trial Phase I - HIV + patients
Clinical Trials
Human Immunodeficiency Virus (HIV)
• Anti-viral properties ( anti-HIV-1) in vitro
Clinical Trials
HIV /AIDS
• Preliminary clinical study with AIDS patients * *
Clinical Trials
Herpes virus
• Antiviral properties against herpes virus and shingles in humans * *
Human Papiloma Virus (HPV)
• Pilot study in human papilloma virus (HPV) using the immunomodulator P-MAPA * *
Clinical Trials
Cancer
• Rationale for using P-MAPA on cancer patients * *
• Effect of P-MAPA on white blood cell count in cancer patients * *
References
• Bibliographic references ** ( Under construction)